摘要
目的探讨表皮生长因子受体(EGFR)的单克隆抗体尼妥珠单(nimotuzumab,h-R3)与化疗药物联合对结肠癌细胞株LoVo的作用,初步探讨其可能的作用机制。方法采用MTT法测定不同药物单药、两药联合分别对结肠癌细胞株LoVo的IC50值;计算不同药物联合的q值,以确定药物联合的作用;流式细胞仪检测不同药物单药或者联合对细胞周期分布及凋亡比例的影响。结果联合h-R3能显著提高伊立替康对LoVo细胞的细胞抑制率,诱导更多肿瘤细胞发生凋亡以及产生G0/G1期、G2/M期阻滞,与5-氟尿嘧啶联合具有类似的作用,但较伊立替康不明显,而与奥沙利铂联合无明显增效作用。结论h-R3通过协同或相加作用提高伊立替康、氟尿嘧啶的细胞杀伤作用,其机制与促进细胞凋亡和影响细胞周期分布有关,奥沙利铂联合对LoVo细胞无明显增效作用。为进一步的体内及体外实验提供了一定的指导作用。
Objective To investigate the effect and the possible mechanisms of cytotoxic, agents combined with nimotuzumab in human colon LoVo cell line. Methods Inhibition of cell proliferation was evaluated by MTT assay. The combination effect was determined by q value. Cell cycle and apoptosis were analyzed by FACS. Results Combined treatment with h-R3 and nimotuzumab could not only enhance the growth inhibition but also increase apoptosis and cell cycle （G0/G1 and G2/M） arrest of LoVo cells. The effect was less apparent when h-R3 was combined with 5- FU. Enhancing effect was not observed when h-R3 was combined with L-OHP. Conclusion Nimotuzumab could enhance the therapeutic actions of certain chemotherapeutic agents on LoVo cells.
出处
《热带医学杂志》
CAS
2009年第5期483-486,共4页
Journal of Tropical Medicine
基金
广东省自然科学基金(No.30801308)
